INMB
Income statement / Annual
Last year (2024), INmune Bio, Inc.'s total revenue was $14.00 K,
a decrease of 90.97% from the previous year.
In 2024, INmune Bio, Inc.'s net income was -$42.08 M.
See INmune Bio, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$14.00 K |
$155.00 K |
$374.00 K |
$181.00 K |
$10.92 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$14.00 K
|
$155.00 K
|
$374.00 K
|
$181.00 K
|
$10.92 K
|
$77.69 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$33.17 M
|
$20.27 M
|
$17.07 M
|
$20.54 M
|
$5.92 M
|
$3.28 M
|
$1.11 M
|
$435.36 K
|
$101.50 K
|
$0.00
|
| General & Administrative Expenses |
$9.48 M
|
$9.62 M
|
$9.26 M
|
$8.79 M
|
$6.32 M
|
$6.02 M
|
$11.34 M
|
$546.12 K
|
$126.00 K
|
$195.47 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$52.00 K
|
$33.20 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.48 M
|
$9.62 M
|
$9.26 M
|
$8.79 M
|
$6.32 M
|
$6.02 M
|
$9.09 M
|
$546.12 K
|
$126.00 K
|
$48.87 K
|
| Other Expenses |
$0.00
|
$0.00
|
-$1.35 M
|
-$1.19 M
|
$0.00
|
-$1.54 M
|
$0.00
|
-$6.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$42.65 M
|
$29.90 M
|
$26.33 M
|
$29.33 M
|
$12.24 M
|
$7.76 M
|
$12.44 M
|
$981.48 K
|
$227.49 K
|
$48.87 K
|
| Cost And Expenses |
$42.65 M
|
$29.90 M
|
$26.33 M
|
$29.33 M
|
$12.24 M
|
$9.30 M
|
$12.44 M
|
$981.48 K
|
$227.49 K
|
$48.87 K
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$77.69 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$1.35 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$553.00 K
|
$29.74 M
|
$25.95 M
|
$29.15 M
|
$12.23 M
|
$9.30 M
|
$12.44 M
|
$981.48 K
|
$227.49 K
|
$195.47 K
|
| EBITDA |
-$42.08 M |
-$29.74 M |
-$25.95 M |
-$29.15 M |
-$12.23 M |
$0.00 |
$0.00 |
$149.99 K |
-$50.00 K |
$146.60 K |
| EBITDA Ratio |
-3005.86
|
-191.88
|
-69.39
|
-161.07
|
-1120.19
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-3045.36
|
-191.88
|
-69.39
|
-161.07
|
-1120.19
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$553.00 K
|
-$267.00 K
|
-$1.35 M
|
-$1.19 M
|
$129.00 K
|
$77.69 K
|
$0.00
|
$149.99 K
|
-$50.00 K
|
$0.00
|
| Income Before Tax |
-$42.08 M
|
-$30.01 M
|
-$27.30 M
|
-$30.34 M
|
-$12.10 M
|
-$7.68 M
|
-$12.44 M
|
-$831.00 K
|
-$277.00 K
|
-$48.87 K
|
| Income Before Tax Ratio |
-3005.86
|
-193.6
|
-72.99
|
-167.62
|
-1108.39
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$1.35 M
|
-$29.15 M
|
-$12.23 M
|
$1.46 M
|
-$161.00 K
|
-$1.13 M
|
-$177.00 K
|
$0.00
|
| Net Income |
-$42.08 M
|
-$30.01 M
|
-$27.30 M
|
-$30.34 M
|
-$12.10 M
|
-$7.68 M
|
-$12.44 M
|
-$831.00 K
|
-$277.00 K
|
-$48.87 K
|
| Net Income Ratio |
-3005.86
|
-193.6
|
-72.99
|
-167.62
|
-1108.37
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.08 |
-1.67 |
-1.52 |
-1.88 |
-1.01 |
-0.89 |
-1.11 |
-0.0741 |
-0.0247 |
-0.0044 |
| EPS Diluted |
-2.08 |
-1.67 |
-1.52 |
-1.88 |
-1.01 |
-0.89 |
-1.11 |
-0.0741 |
-0.0247 |
-0.0044 |
| Weighted Average Shares Out |
$19.94 M
|
$17.98 M
|
$17.93 M
|
$16.13 M
|
$11.99 M
|
$10.27 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
| Weighted Average Shares Out Diluted |
$19.94 M
|
$17.98 M
|
$17.93 M
|
$16.13 M
|
$11.99 M
|
$10.27 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
$11.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
